Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $16.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC decreased their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Trading Up 10.2 %

Shares of ESPR opened at $2.80 on Wednesday. The firm’s fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $2.16. Esperion Therapeutics has a 12 month low of $1.27 and a 12 month high of $3.40. The stock has a market capitalization of $551.71 million, a P/E ratio of -4.38 and a beta of 0.96.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Eaton Financial Holdings Company LLC bought a new position in shares of Esperion Therapeutics in the 3rd quarter worth $73,000. Barclays PLC lifted its stake in shares of Esperion Therapeutics by 99.6% in the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 154,509 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics during the third quarter worth about $606,000. Finally, Anson Funds Management LP acquired a new stake in shares of Esperion Therapeutics in the 3rd quarter worth about $540,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.